-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Defu Medical Publishing House published the latest article in the Journal of Drug Design, Development and Therapy.
International Clinical Trial Registration Platform Antiviral Drugs for the Treatment of COVID-19 Clinical Trial Design Features and Pharmacological Mechanisms.
The contents are summarized as follows: Purpose: This study aims to evaluate Research design features and pharmacological mechanisms of antiviral drugs registered on the International Clinical Trial Registration Platform (ICTRP) for the treatment of new coronavirus disease (COVID-19).
Methods: Retrieve clinical trials of antiviral drugs for the treatment of COVID-19 through the ICTRP registration platform, and evaluate the research design, number of subjects, main indicators, clinical trial registration sources, antiviral mechanisms and clinical trial results of antiviral drug clinical trials.
Results: As of June 10, 2020, the ICTRP registration platform has retrieved 145 clinical trials of antiviral drugs for the treatment of COVID-19, including 99 randomized trials (68.
3%) and 109 parallel design trials (75.
2%).
38 double-blind and single-blind trials (26.
2%), 130 trials (89.
7%) in two groups, 75 trials with more than 100 subjects (51.
6%); clinical symptoms improved or recovered Virus and virus negative conversion are the two most common main indicators, accounting for 40.
7% and 18.
6% respectively.
These antiviral drugs are classified into HIV reverse transcriptase inhibitors, RNA replicase inhibitors, HIV protease inhibitors (PIs), hepatitis C virus NS3 PIs and anti-influenza drugs according to their antiviral mechanisms.
Conclusion: This study evaluated the clinical trial design features, pharmacological mechanisms, and antiviral clinical efficacy of antiviral drugs for the treatment of COVID-19.
The results of this study can provide references for future COVID-19 treatment and prevention.
Keywords: COVID-19, clinical trials, antiviral agents, research design, follow the German video applet, more exciting abstract videos waiting for you to discover
International Clinical Trial Registration Platform Antiviral Drugs for the Treatment of COVID-19 Clinical Trial Design Features and Pharmacological Mechanisms.
The contents are summarized as follows: Purpose: This study aims to evaluate Research design features and pharmacological mechanisms of antiviral drugs registered on the International Clinical Trial Registration Platform (ICTRP) for the treatment of new coronavirus disease (COVID-19).
Methods: Retrieve clinical trials of antiviral drugs for the treatment of COVID-19 through the ICTRP registration platform, and evaluate the research design, number of subjects, main indicators, clinical trial registration sources, antiviral mechanisms and clinical trial results of antiviral drug clinical trials.
Results: As of June 10, 2020, the ICTRP registration platform has retrieved 145 clinical trials of antiviral drugs for the treatment of COVID-19, including 99 randomized trials (68.
3%) and 109 parallel design trials (75.
2%).
38 double-blind and single-blind trials (26.
2%), 130 trials (89.
7%) in two groups, 75 trials with more than 100 subjects (51.
6%); clinical symptoms improved or recovered Virus and virus negative conversion are the two most common main indicators, accounting for 40.
7% and 18.
6% respectively.
These antiviral drugs are classified into HIV reverse transcriptase inhibitors, RNA replicase inhibitors, HIV protease inhibitors (PIs), hepatitis C virus NS3 PIs and anti-influenza drugs according to their antiviral mechanisms.
Conclusion: This study evaluated the clinical trial design features, pharmacological mechanisms, and antiviral clinical efficacy of antiviral drugs for the treatment of COVID-19.
The results of this study can provide references for future COVID-19 treatment and prevention.
Keywords: COVID-19, clinical trials, antiviral agents, research design, follow the German video applet, more exciting abstract videos waiting for you to discover
